caa a22 4500 60615518X CHVBK 20210128100602.0 cr unu---uuuuu 210128e20150101xx s 000 0 eng 10.1007/s10096-014-2208-6 doi (NATIONALLICENCE)springer-10.1007/s10096-014-2208-6 Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? [Elektronische Daten] [A. Torres, P. Bonanni, W. Hryniewicz, M. Moutschen, R. Reinert, T. Welte] Individuals <2years and ≥50years of age, as well as those with other specific risk factors, are especially vulnerable to invasive pneumococcal disease (IPD). Conjugate vaccines have been developed against encapsulated bacteria such as Streptococcus pneumoniae to provide improved immune responses. The 7-valent pneumococcal conjugate vaccine (PCV7) has significantly reduced the burden of vaccine-type pneumococcal diseases in children, including invasive disease and pneumonia and acute otitis media. There have also been significant declines in antimicrobial resistance in 7-valent vaccine serotypes and carriage of S. pneumoniae in the post-PCV7 era. Two to threeyears after the introduction of PCV13, there is emerging, global evidence of a reduced burden of pneumococcal diseases in children, including declines in IPD (UK and Germany) and nasopharyngeal carriage of PCV13 serotypes (Portugal and France). The functional immunogenicity of PCV13 in individuals ≥50years of age has been demonstrated in clinical trials in comparison with the 23-valent pneumococcal polysaccharide vaccine and for children and adults 6 to 49years of age. Between 2011 and 2013, PCV13 received market authorisation by the European Medicines Agency (EMA) for these additional age groups and is now available in Europe for the prevention of pneumococcal disease in all age groups. The Author(s), 2014 Torres A. Servei de Pneumologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBER de Enfermedades Respiratorias (CIBERes), University of Barcelona, Barcelona, India aut Bonanni P. Department of Health Sciences, University of Florence, Florence, Italy aut Hryniewicz W. National Medicines Institute, Warsaw, Poland aut Moutschen M. Department of Infectious Diseases and General Internal Medicine, CHU de Liège/University of Liège, Liège, Belgium aut Reinert R. Pfizer Vaccines (Medical Development Group and Scientific Affairs), Paris, France aut Welte T. Klinic für Pneumologie, Medizinische Hochschule Hannover, Hannover, Germany aut European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/1(2015-01-01), 19-31 0934-9723 34:1<19 2015 34 10096 https://doi.org/10.1007/s10096-014-2208-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10096-014-2208-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Torres A. Servei de Pneumologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBER de Enfermedades Respiratorias (CIBERes), University of Barcelona, Barcelona, India aut NATIONALLICENCE 700 1- Bonanni P. Department of Health Sciences, University of Florence, Florence, Italy aut NATIONALLICENCE 700 1- Hryniewicz W. National Medicines Institute, Warsaw, Poland aut NATIONALLICENCE 700 1- Moutschen M. Department of Infectious Diseases and General Internal Medicine, CHU de Liège/University of Liège, Liège, Belgium aut NATIONALLICENCE 700 1- Reinert R. Pfizer Vaccines (Medical Development Group and Scientific Affairs), Paris, France aut NATIONALLICENCE 700 1- Welte T. Klinic für Pneumologie, Medizinische Hochschule Hannover, Hannover, Germany aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/1(2015-01-01), 19-31 0934-9723 34:1<19 2015 34 10096